- Home
- OTLK vs ATNM Comparison
OTLK vs ATNM Comparison
Compare OTLK & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ATNM
- Stock Information
- Founded
- OTLK 2010
- ATNM 2000
- Country
- OTLK United States
- ATNM United States
- Employees
- OTLK N/A
- ATNM N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- ATNM Health Care
- Exchange
- OTLK Nasdaq
- ATNM Nasdaq
- Market Cap
- OTLK 48.3M
- ATNM 51.5M
- IPO Year
- OTLK 2016
- ATNM N/A
- Fundamental
- Price
- OTLK $2.25
- ATNM $1.73
- Analyst Decision
- OTLK Strong Buy
- ATNM Strong Buy
- Analyst Count
- OTLK 5
- ATNM 3
- Target Price
- OTLK $9.60
- ATNM $4.67
- AVG Volume (30 Days)
- OTLK 987.3K
- ATNM 465.3K
- Earning Date
- OTLK 08-13-2025
- ATNM 08-04-2025
- Dividend Yield
- OTLK N/A
- ATNM N/A
- EPS Growth
- OTLK N/A
- ATNM N/A
- EPS
- OTLK 0.83
- ATNM N/A
- Revenue
- OTLK N/A
- ATNM N/A
- Revenue This Year
- OTLK N/A
- ATNM N/A
- Revenue Next Year
- OTLK $419.06
- ATNM N/A
- P/E Ratio
- OTLK $2.62
- ATNM N/A
- Revenue Growth
- OTLK N/A
- ATNM N/A
- 52 Week Low
- OTLK $0.87
- ATNM $1.03
- 52 Week High
- OTLK $9.10
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- OTLK 67.03
- ATNM 56.59
- Support Level
- OTLK $2.16
- ATNM $1.48
- Resistance Level
- OTLK $2.45
- ATNM $1.69
- Average True Range (ATR)
- OTLK 0.16
- ATNM 0.09
- MACD
- OTLK 0.05
- ATNM 0.02
- Stochastic Oscillator
- OTLK 81.01
- ATNM 88.24
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.